Some, but not all, studies have demonstrated an increased risk of miscarriage among women who take antidepressants. However, it has been difficult to determine whether this increased risk was related to exposure to the medication [...]
A recent report suggests that epidural labor analgesia is associated with a decreased risk of postpartum depression (PPD). This prospective study included 214 pregnant women from Beijing, China who were preparing for a vaginal delivery. Epidural [...]
While we are advocating universal screening for perinatal mood and anxiety disorders, it is unclear if we have the ability to provide mental health services to this population in need. One significant obstacle to treatment [...]
Bupropion is commonly used to treat depression, and is also prescribed to support smoking cessation. Early data on bupropion-exposure during pregnancy raised concern for a possible increase in risk of malformations of the heart and large blood vessels in bupropion-exposed infants. Subsequent data from bupropion pregnancy registries has been reassuring, however, and do not demonstrate an overall increase in risk of cardiac defects following first trimester bupropion exposure. Although the overall risk of cardiac defects was not increased, the distribution of specific defects in these registries was unexpected in some ways. For example, the GlaxoSmithKline Bupropion Pregnancy Registry included two cases of coarctation of the aorta out of the 675 bupropion-exposed infants, compared to the rate of 6 cases per 10,000 births in the general population.
Although postpartum depression (PPD) affects about 15% of all women after the birth of a child, most women with PPD receive no treatment. One of the problems has been inadequate screening for perinatal mood and anxiety disorders. Over the last decade, there has been an emphasis on educating health care professionals to reliably screen for PPD; however, other obstacles to obtaining treatment remain. Many women cannot find appropriate treaters in their area. Others are not able to get childcare in order to attend weekly appointments. Given these limitations, it is important that we explore other types of interventions that might be used to reach and effectively treat women with PPD.
We have received many emails and calls from colleagues and patients regarding the recent article on the safety of SSRI use during pregnancy published in the New York Times. In this article, health writer Roni Caryn Rabin, detailed the risks associated with the use of antidepressants during pregnancy.
For decades, researchers have postulated a connection between breastfeeding and postpartum depression (PPD). Many have suggested that breastfeeding may protect against postpartum depression and have suggested that the cessation of breastfeeding may be a trigger [...]
Last year, the FDA approved the first non-hormonal treatment for hot flashes – a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine which was marketed under the name of Brisdelle. A new study [...]
Current research suggests that women with premenstrual dysphoric disorder (PMDD) have an abnormal affective response to normal hormonal shifts that occur during the menstrual cycle. Some researchers have hypothesized a metabolite of progesterone (PROG), allopregnanolone [...]
Benzodiazepines and non-benzodiazepine hypnotics are commonly used during pregnancy. However, there data regarding the reproductive safety of these agents has been somewhat mixed. Although initial reports suggested that there may be an increased risk of cleft lip and palate, more recent reports have shown no association between exposure to benzodiazepines and risk for cleft lip or palate. A new study shows no increase in the overall risk of malformations among children exposed to benzodiazepines.
